Both in adjuvant as well as in neoadjuvant therapy, maintrac® can help to monitor breast cancer therapy and make an optimization if required.

With maintrac® the effectiveness of chemotherapeutic agents can already be tested prior to the colon cancer treatment.

maintrac® is able to support the control of therapy success and helps choosing promising therapy strategies regarding the stage of disease and treatment.

With the possibility of testing various substances with maintrac®, the patient already gets to know the substance most likely to be effective against the CETCs even before starting chemotherapy.

In particular in the situation of watch-and-wait in prostate cancer, maintrac® can be applied for active surveillance.

After cancer therapy is successfully accomplished, the calculated course of cell counts of maintrac® can be an indication wheter stomach cancer stays in remission or is about to return.

With maintrac® it is possible to identify the drug which is likely to be most effective prior to the therapy.

Certain substances (targeted tumor therapies) only prove useful if tumor cells exhibit the relevant properties.

In addition to the monitoring of therapy success, maintrac® is able to identify medications which are most probable to be effective on the circulating tumor cells in the blood.

In the metastatic situation, the maintrac® cell courses should be interpreted individually due to various possibilities of interpretation.

During hormone and maintenance therapy, maintrac® can also support the monitoring of cancer diseases as well as the decision making concering further therapies.